"Short term, if you're visiting a smaller biotech customer, what you're seeing is concerns about when the funding environment is going to improve.
On the call, finance chief Stephen Williamson said core revenue growth and adjusted profit in 2024 will be similar to that in 2023.
It also forecast 2023 adjusted profit of $21.50 per share, below analysts' estimates of $22.28.
The medical equipment maker forecast adjusted earnings of $21.75 per share in 2024, short of analysts' estimates by $2.23.
Third-quarter revenue of $10.57 billion missed analysts' expectations of $10.60 billion while adjusted profit of $5.69 per share topped estimates of $5.61, according to LSEG data.
Persons:
Brian Snyder, Marc Casper, Stephen Williamson, Raymond James, Andrew Cooper, Bhanvi, Shinjini Ganguli, Shounak Dasgupta, Sriraj
Organizations:
REUTERS, Agilent Technologies, Reuters, Thomson
Locations:
Waltham , Massachusetts, U.S, China, Bengaluru